The influence of symptom experiences and attributes on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow up study by Cooper, V. et al.
  
PLEASE SCROLL DOWN FOR ARTICLE
This article was downloaded by: [King's College London]
On: 4 June 2009
Access details: Access Details: [subscription number 788785078]
Publisher Routledge
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
AIDS Care
Publication details, including instructions for authors and subscription information:
http://www.informaworld.com/smpp/title~content=t713403300
The influence of symptom experiences and attributions on adherence to highly
active anti-retroviral therapy (HAART): a six-month prospective, follow-up study
V. Cooper a; G. Gellaitry a; M. Hankins b; M. Fisher c; R. Horne a
a
 Department of Policy and Practice, Centre for Behavioural Medicine, School of Pharmacy, University of
London, Tavistock Square, London b Department of Psychology, Institute of Psychiatry, King's College
London, London, UK c Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
Online Publication Date: 01 April 2009
To cite this Article Cooper, V., Gellaitry, G., Hankins, M., Fisher, M. and Horne, R.(2009)'The influence of symptom experiences and
attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study',AIDS
Care,21:4,520 — 528
To link to this Article: DOI: 10.1080/09540120802301824
URL: http://dx.doi.org/10.1080/09540120802301824
Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf
This article may be used for research, teaching and private study purposes. Any substantial or
systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or
distribution in any form to anyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation that the contents
will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses
should be independently verified with primary sources. The publisher shall not be liable for any loss,
actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly
or indirectly in connection with or arising out of the use of this material.
The inﬂuence of symptom experiences and attributions on adherence to highly active
anti-retroviral therapy (HAART): a six-month prospective, follow-up study
V. Coopera, G. Gellaitrya, M. Hankinsb, M. Fisherc and R. Hornea*
aDepartment of Policy and Practice, Centre for Behavioural Medicine, School of Pharmacy, University of London,
BMA House, Tavistock Square, London; bDepartment of Psychology, Institute of Psychiatry, King’s College London,
London, UK; cBrighton and Sussex University Hospitals NHS Trust, Brighton, UK
(Received 3 April 2007; final version received 25 June 2008)
Objective. To examine changes in individuals’ experiences of symptoms over the first six months of taking highly
active anti-retroviral therapy (HAART) and to assess the impact of symptom experiences and attributions on
adherence to HAART. Methods. A prospective study where consecutive HIV positive individuals initiating
HAART completed validated questionnaires assessing their experiences of symptoms, depression, beliefs about
HAART and adherence, before starting treatment and after one, three and six months of treatment. Results.
Rates of low (B95%) adherence to HAART increased over time (pB0.001). Overall, the number of HIV or
HAART-related symptoms reported did not change significantly over follow-up. However, symptom experiences
differed between those reporting high (]95%) adherence and those reporting low adherence. Individuals
reporting high adherence experienced a decrease in symptoms they attributed to HIV (pB0.05), and a decrease in
the symptoms they attributed to HAART-side effects (pB0.05) over time. This decrease in symptoms over time
was not seen among individuals reporting low adherence. A lack of symptomatic improvement was associated
with increasing doubts about the continued necessity for HAART (pB0.05). Conclusions. The findings suggest
that adherence to HAART is influenced by individuals’ experiences of both HIV and HAART-related symptoms.
Patients who experience persistent symptoms while on HAART may begin to doubt their continued need for
treatment and respond by missing doses. These findings have implications for the development of evidence-based
interventions to increase adherence.
Keywords: adherence; HIV; HAART; symptoms; side effects; treatment perceptions
Introduction
Highly active anti-retroviral therapy (HAART) has
greatly reduced morbidity and mortality associated
with HIV (Mocroft et al., 2003) however, low
adherence seriously compromises the efficacy of this
treatment (Paterson et al., 2000; Wood et al., 2003).
Maintaining high levels of adherence over long-term
often proves difficult (Golin et al., 2002; Gross,
Bilker, Friedman, & Strom, 2001). Identifying ante-
cedents of non-adherence is crucial in order to
develop effective strategies to help people to achieve
maximum benefit from HAART. While recent devel-
opments in the formulation of antiretroviral medi-
cines have addressed some of the practical barriers to
adherence, HAART continues to carry the risk of
unpleasant or intolerable side effects. Even the most
simple drug regimen may pose problems for adher-
ence if it makes the individual feel worse or does not
improve symptoms.
Symptoms are common among individuals re-
ceiving HAART (Bonfanti et al., 2000; Lucas,
Chaisson, & Moore, 1999) and have been associated
with both non-adherence (Ammassari et al., 2001;
Chesney et al., 2000) and discontinuation of HAART
(Mocroft et al., 2001; O’Brien, Clark, Besch, Myers,
& Kissinger, 2003). In order to develop appropriate
interventions, several methodological issues need to
be addressed. Most studies to date have been cross-
sectional and therefore it was not possible to deter-
mine the direction of associations between symptoms
and non-adherence. Little is known about how
symptoms change over time or what impact such
changes have on adherence. Most studies failed to
distinguish between treatment side effects and dis-
ease-related symptoms. We need to understand the
subjective distinction between symptoms of disease
and side effects of treatment in order to inform efforts
to help individuals cope with symptoms and improve
the management of side effects. Studies have not
adjusted for the possible influence of depression in
their analyses, yet depression is common among
people with HIV (Ciesla & Roberts, 2001) and may
impact on both symptom experiences (Watson &
Pennebaker, 1989) and adherence (Ammassari et al.,
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2004). Finally, the mechanisms by which symptoms
impact on adherence have not been adequately
explored.
The self-regulatory model (SRM) (Leventhal &
Cameron, 1987; Leventhal, Nerenz & Sraus, 1992)
proposes that illness-related behaviours are influ-
enced by the way in which individuals interpret their
symptom experiences. Within this model, non-adher-
ence is viewed as a ‘‘common sense’’ response to a
lack of coherence between individuals’ beliefs about
the illness, their experience of symptoms and the
doctor’s instructions. A qualitative study provided
support for this model (Siegel, Schrimshaw, & Dean,
1999), with individuals reporting that they missed
doses of their antiretroviral treatment in order to
avoid side effects, and were prepared to accept the
consequence of reduced clinical benefit.
Horne (1997, 2003) proposed a method for
operationalising the SRM to explain variations in
adherence to medication. He suggests that adherence
is influenced by the way in which the individuals
judge their personal need for treatment relative to
their concerns about potential adverse effects. These
judgements are influenced by the individual’s percep-
tion of their illness and their interpretation of
symptom experiences. Previous research in a range
of conditions including HIV (Aikens, Nease, Nau,
Klinkman & Schwenk, 2005; Brown et al., 2005,
Horne & Weimnan, 2002; Horne et al., 2004, 2007;
Llewellyn, Miners, Lee, Harrington & Weinman,
2003; Neame & Hammond, 2005) has provided
support for the necessity-concerns framework
(NCF) in relation to adherence, however, little is
known about how patients’ experiences of symptoms
impact on their beliefs about HAART.
The aims of this study were to (1) explore
individuals’ differential attributions of symptoms to
HIV or HAART; (2) explore changes in subjective
experiences of HIV and HAART-related symptoms
over time; and (3) examine associations between
symptoms and beliefs about HAART over time.
Methods
Design
Patients attending an outpatient HIV clinic in
Brighton, UK, completed validated questionnaires
assessing their adherence, experiences of symptoms
and beliefs about HAART before initiating treatment
(0M) and after one (1M), three (3M) and six months
(6M). Data was collected between January 2000 and
May 2004.
Participants
Patients were eligible for the study if they were not
currently taking antiretroviral medication. Partici-
pants were followed up over a year, and those who
subsequently accepted a clinically indicated offer of
HAART formed the sample for this study. Exclusion
criteria included having insufficient understanding of
English or being too ill to complete the study
questionnaires.
Procedure
Consecutive study-eligible individuals were referred
by their HIV physician to a research assistant.
Standard procedures for consent were followed.
Researchers attended weekly clinical meetings to
identify participants who were eligible for a HAART
recommendation on the basis of contemporaneous
guidelines (British HIV Association, 1997, 2001,
2003). Following a treatment recommendation, par-
ticipants were given a questionnaire booklet to
complete along with a stamped addressed envelope.
Medical files and pharmacy records were consulted to
identify those who initiated HAART. These partici-
pants were sent follow-up questionnaires one month
(1M), three months (3M) and six months (6M) after
initiating treatment. Telephone reminders were ad-
ministered to optimise response rates.
Measures
Adherence
Adherence to HAART was measured using the
Medication Adherence Self Report Inventory
(MASRI) (Walsh, Mandalia & Gazard, 2002). Parti-
cipants were asked to estimate on a visual analogue
scale of 0100 the percentage of medication they had
taken as prescribed over the previous month. Parti-
cipants who reported taking less than 95% of
HAART medicines were allocated to a ‘‘low adher-
ence’’ group, and those taking 95% or more of their
medication as prescribed allocated to a ‘‘high adher-
ence’’ group (Paterson et al., 2000).
Symptom experiences and attributions
Symptom experiences were assessed using the Identity
subscale of the Illness Perceptions Questionnaire
(IPQ) (Moss-Morris et al., 2002; Weinman, Petrie,
Moss-Morris & Horne, 1996) comprising 11 ‘‘core’’
symptoms common to a variety of illnesses and
modified by the addition of 12 common HIV/
HAART-related symptoms. There were two symp-
tom scales, each comprising the same 23 symptoms.
On one list, participants were asked to rate only those
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symptoms they believed to result from HIV. On a
second list, participants were asked to rate only those
symptoms they associated with HAART. The scoring
was conducted by first asking whether the person was
experiencing the symptom (yes/no) and second, by
asking the participants to rate the severity of each
symptom they experienced on a scale of 15, where
1very mild, 2mild, 3moderate, 4severe, 5
very severe. To ensure that only symptoms that were
troublesome to the individual were included, only
scores rated 35 were used in the analyses, thereby
excluding symptoms rated as ‘‘mild’’ or ‘‘very mild’’.
Possible scores ranged from 0 to 23, representing the
number of symptoms the patient perceived to be
moderate, severe or very severe.
Beliefs about HAART
Beliefs about HAART were assessed using the Beliefs
about Medicines Questionnaire-HAART specific ver-
sion (BMQ-HAART) (Horne, Weinman & Hankins,
1999; Horne et al., 2004, 2007). The BMQ-HAART
comprises two scales: a HAART-necessity scale
assessing individuals’ perceptions of their personal
need for HAART for controlling HIV and maintain-
ing health, and a HAART-concerns scale, assessing
concerns about potential adverse effects of HAART
(e.g. worries about short and long-term side effects
and concerns about the disruptive effects of the
HAART regimen on daily life). These were derived
from studies of patients’ perceptions of HAART
(Cooper et al., 2002; Horne et al, 2004).
Participants were presented with a series of state-
ments and asked to rate their level of agreement with
each item on a scale, where responses ranged from
strongly agree (scored 5) to strongly disagree (scored
1). Scores for individual items within each scale were
summed. A mean score was computed by dividing
each total by the number of items, giving a range of
one to five for both necessity and concerns scales.
Depression
The depression subscale of the Hospital Anxiety and
Depression Scale (HADS) (Zigmond & Snaith, 1983)
was used to measure patients’ experience of depres-
sive symptoms over the previous month. Possible
total scores range from 0 to 21, with higher scores
indicating greater depression.
Clinical and demographic data
Clinical and demographic information, including age,
sex, employment status, HIV acquisition risk, num-
ber of years since first HIV diagnosis, symptom
classification (asymptomatic HIV, symptomatic
HIV or AIDS), whether the person had previously
been prescribed antiretroviral treatment, CD4 count
and viral load (log10), was extracted from partici-
pants’ medical files.
Statistical methods
Data were analysed using SPSS† 12.0 (SPSS Inc,
Chicago, Ill). Clinical and demographic characteristics
were compared between those who completed the
study and those with missing data, using chi-square
tests for categorical data and independent samples
t-tests for continuous variables. Clinical and demo-
graphic associations with adherence were also exam-
ined in this way. NcNemar’s test was used to compare
the number of patients reporting low adherence at 1M
and 6M. The frequency of individual symptoms was
compared between high and low adherence groups
using chi-square tests. Repeated measures ANCOVA
was used to assess changes in symptom experiences
over time and the impact of these changes on adherence
at 6M, controlling for clinical variables that were
associated with adherence in the univariate analyses
(prior antiretroviral use and time sinceHIV diagnosis),
baseline depression and adherence at 1M and 3M.
Estimated marginal means (EMMs) were plotted.
Associations between changes in symptoms and med-
ication beliefs were assessed using Pearson’s correla-
tions and residualised change scores between baseline
and six months measures (Cohen & Cohen, 1983).
Results
Subjects
One hundred and twenty participants initiated
HAART. Over the follow-up, 10 participants stopped
treatment, two died, 10 were lost to follow up and 18
missed one or more follow-up assessment or returned
questionnaires with missing data (Figure 1). Eighty
participants (66.7%) provided the data for this study.
Clinical and demographic characteristics of the
sample are shown in Table 1.
Validity of adherence measure
Fifty-nine (96.7%) of those reporting high adherence
at one month had an undetectable viral load (B50
copies/ml) at six months compared to 16 (84.2%) of
those reporting low adherence (x23.87, pB0.05).
Predictors of adherence
The number of participants reporting low adherence
increased from 5 (6.3%) at 1M to 17 (21.3%) at 6M
(McNemar’s test: pB0.001). Low adherence at 6M
was associated with having been diagnosed for a
522 V. Cooper et al.
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longer time (F (1,79)5.94, pB0.05) and having
previously been prescribed antiretroviral medication
(x210.6, pB0.001).
Symptom attributions and impact on adherence
The 12 symptoms (rated moderate-severe) most
commonly attributed to HIV and HAART at 6M
are shown in Figure 2. No individual symptoms were
more frequently attributed to HIV or HAART
(McNemar’s test, all p0.05).
Symptoms attributed to HIV
At baseline, 66 (82.5%) participants reported ]1
moderate-severe symptom they attributed to HIV.
The number of symptoms reported ranged from 0 to
21 (mean5.1, SD4.5). At 6M, 42 (58.8%) parti-
cipants reported ]1 moderate to severe symptom
BASELINE Accept HAART n=120
Complete questionnaires:Symptoms checklists, HADS, BMQ-HAART 
1-MONTH FOLLOW-UP (n=111)
Symptoms checklist, BMQ-HAART, MASRI
3 stopped treatment
1 died
2 dropped out 
3 MONTH FOLLOW_UP (n=105)
Symptoms checklist, BMQ-HAART, MASRI
5 stopped treatment
2 dropped out
6 MONTH FOLLOW-UP(n=98)
Complete Symptoms checklist, BMQ-HAART, MASRI
80 (66.7%) complete questionnaires at all time-points
2 stopped treatment
1 died
6 dropped out 
Figure 1. Study design and attrition.
Table 1. Sample demographics and clinical characteristics.
Baseline clinical/demographic feature
Completed study
n80
Missing data
n40 P
Age (years) Mean (SD) 40.0 (8.7) 34.0 (6.1) B0.001
Transmission risk: gay man n (%) 74 (92.5) 34 (85.0) 0.1
White British n (%) 70 (87.5) 27 (77.1) 0.1
Years since HIV diagnosis Mean (SD) 4.1 (4.2) 4.5 (5.0) 0.1
Asymptomatic HIV n (%) 25 (31.3) 12 (30.0) 0.1
Symptomatic HIV n (%) 36 (45.0) 15 (37.5) 0.1
AIDS n (%) 19 (23.8) 13 (32.5) 0.1
Prior experience of ART n (%) 22 (27.5) 22 (55.0) B0.005
CD4 count (mm3/L) Mean (SD) 204 (131) 176 (124) 0.1
Viral load (log10 copies/ml) Mean (SD) 5.3 (0.5) 5.3 (0.5) 0.1
Moderate-severe symptoms (HIV) Mean (SD) 5.1 (4.6) 5.6 (5.0) 0.1
HAART-necessity Mean (SD) 4.0 (0.5) 3.6 (0.6) B0.001
HAART-concerns Mean (SD) 3.0 (0.6) 3.2 (0.6) 0.05
HADS-depression Means (SD) 5.2 (4.3) 7.5 (4.7) B0.01
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they attributed to HIV, the number ranged from 0 to
17 (mean3.0, SD4.2).
Symptoms attributed to HAART-side effects
At 1M, 59 (73.8%) participants reported ]1 mod-
erate to severe symptom they attributed to HAART.
The number of symptoms reported ranged from 0 to
17 (mean3.8, SD4.3). At 6M, 47 (58.8%) of
participants reported ]1 moderate to severe symp-
tom they attributed to HAART. The number of
symptoms ranged from 0 to 17 (mean3.2, SD
4.4).
Relationships between symptom experiences and
adherence
In cross-sectional analyses assessing the relationships
between symptom experiences and adherence at six
months, a greater number of symptoms associated
with both HIV (t (78)2.249, pB0.05) and HAART
(t (78)2.490, pB0.05) were associated with low
adherence. Individual HAART-related symptoms
associated with low adherence were night-sweats
(pB0.01) and sexual problems (pB0.001). Individual
HIV-related symptoms associated with low adherence
were: fatigue (pB0.01), sleep difficulties and altered
sensation in hands or feet (all pB0.05).
In repeated measures analysis, there was no
significant main effect of time (F(1,66)0.17, p
0.1) or group (F(1,66)0.11, p0.1) on HIV-related
symptoms. There was, a significant group by time
interaction (F(1,66)5.0, pB0.05). Figure 3 shows
the main effects and interaction (also reported in
Table 2).
There was no significant main effect of time
(F(1,66)0.03, p0.1) or group (F(1,66)1.07,
p0.1) on HAART-side effects. There was a sig-
nificant group by time interaction (F(1,66)4.1,
pB0.05). Figure 4 shows the main effects and
interaction (also reported in Table 2).
Associations between symptoms and beliefs about
HAART
There was a significant inverse correlation between
changes in symptom experiences and changes in
necessity scores over time (HIV-symptoms r
0.22, pB0.05; HAART symptoms r0.22,
pB0.05), consistent with an increase in symptoms
being associated with a decrease in perceived neces-
sity for HAART. Neither the change in HIV symp-
toms (r0.09, p0.1) nor change in HAART
symptoms (r0.14, p0.1) had a significant impact
on individuals’ concerns about HAART.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
pain (19%)
stiff joints (20%)
nausea (20%)
upset stomach (21%)
altered sensation in hands/feet (21%)
loss of strength (21%)
night sweats (24%)
diarrhoea (25%)
sexual problems (30%)
skin problems (30%)
sleep difficulties (33%)
fatigue (35%)
HIV only HAART only Both HIV and HAART
Figure 2. Causal attribution of moderate-severe symptoms to HIV, HAART or both at six months.
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Figure 3. Adjusted means for number of HIV symptoms
reported.
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Discussion
Low adherence to HAART was associated with
changes in individuals’ subjective experiences of sym-
ptoms over time. People who experienced a lack of im-
provement in either the symptoms they attributed to
HIV or to HAART over the first six months of tre-
atment were more likely to report low adherence.
The results are consistent with previous findings
linking symptoms to non-adherence to HAART
(Ammassari et al., 2001, Carrieri et al., 2001; Chesney
et al., 2000; Duran et al., 2001; Gifford et al., 2000)
and provide further insight into the nature of these
relationships. First, they show that the pattern of
relationships between symptom experiences and ad-
herence was similar with respect to both HIV and
HAART-related symptoms. This finding is consistent
with the SRM (Leventhal et al., 1982, 1987) suggest-
ing that low adherence results from a lack of
coherence between patients’ expectations of treat-
ment and their experience of symptoms. Second, the
findings suggest a possible pathway through which
symptom experiences may impact on adherence. In
line with the model proposed by Horne (1997, 2003),
they suggest that individuals who experience persis-
tent symptoms after initiating HAART may begin to
doubt their need for HAART and respond with low
adherence. Third, we showed that the results were
unlikely to be an artefact due to depressed mood.
Finally, the fact that relationships between symptoms
and adherence remained statistically significant when
earlier adherence was controlled for in the analysis is
consistent with the experience of persistent side
effects leading to non-adherence, rather than symp-
toms being the result of earlier non-adherence.
This study has several limitations. The sample
consisted of predominately gay men. In order to be
representative of the wider HIV positive population
in the UK, the study should be replicated among
other groups. Those who provided data were sig-
nificantly older and more likely to be antiretroviral
naı¨ve than the overall study sample. Since younger
age (Carrieri et al., 2001; Moatti et al., 2000) and
having prior experience of antiretroviral treatment
(Duran et al., 2001; Mannheimer, Friedland, Matts,
Child & Chesney, 2002) have previously been asso-
ciated with non-adherence, it is likely that non-
adherence was underestimated in this study. The
symptom measure did not encompass the wide
spectrum of symptoms that may be experienced by
people living with HIV and those using HAART (e.g.
CNS disturbance). It is therefore possible that some
participants could have been experiencing one or
more severe symptom that was not covered by the
measure. Furthermore, we did not explore experi-
ences of side effects that occur with longer-term use
of HAART, such as lipodystrophy. Depressed mood
was measured only at baseline. In order to fully
control for the possible influence of depression on
self-reported symptoms and adherence, future studies
should control for depression at every time-point.
Table 2. Adjusted means for number of HIV and HAART
symptoms reported. The adjusted mean is the value of the
group mean adjusted for prior treatment experience, time
since diagnosis, baseline depression and adherence at 1M
and 3M.
Moderate-severe HIV-related symptoms
Adherence group Follow-up Mean 95% CI
High baseline 5.1 4.06.2
High one month 4.3 3.05.6
High three months 2.7 1.83.7
High six months 2.4 1.43.4
Low baseline 4.3 1.47.1
Low one month 3.9 0.77.0
Low three months 3.7 1.37.2
Low six months 4.9 2.37.4
Moderate-severe HAART-related symptoms
Adherence group Follow-up Mean 95% CI
High one month 3.8 2.94.8
High three months 2.5 1.53.4
High six months 2.6 1.63.6
Low one month 4.0 1.66.3
Low three months 3.8 1.56.1
Low six months 5.0 2.67.4
1M 3M 6M
2.00
2.50
3.00
3.50
4.00
4.50
5.00
high adherence
low adherence
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Figure 4. Adjusted means for number of HAART symp-
toms reported.
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The study relied heavily on self-report measures,
including a self-report measure of adherence, which
may be subject to a positive bias. Future studies,
using objective measures of adherence are required.
The results of this study only represent two thirds
of the participants originally recruited; those who
remained in the study and on treatment for six
months, and who provided complete data at every
follow-up. It is therefore likely that the sample was
biased in terms of high adherence.
Although our adherence categorisation was sig-
nificantly related to viral suppression, with almost all
(97%) of those in the high adherence group attaining
a viral load B50 copies/ml at the six month follow-
up, 84% of those in the low adherence group also had
an undetectable viral load. In setting our cut-off point
for high adherence we adopted the convention of
95%, current at the time the study was conducted
(Paterson et al., 2000). More recent studies suggest
that viral suppression may be achieved at lower rates
of adherence to boosted protease inhibitor (Gross
et al., 2006) and NNRTI-based regimens (Bangsberg,
2006).
Despite these limitations, our findings support the
idea that non-adherence stems from incongruence
between individuals’ expectations and experiences of
HAART and are consistent with the theory that
symptom experiences influence beliefs about treat-
ment (Horne, 1997, 2003). Specifically, they suggest
that experiencing persistent symptoms attributed to
HIV or developing persistent symptoms related to
HAART leads individuals to doubt their continued
need for HAART and this has been previously
associated with non-adherence (Horne et al., 2007).
Furthermore studies, with larger samples, are re-
quired in order to fully test possible mediational
relationships between symptoms, beliefs about
HAART and adherence.
Our findings are relevant to clinical practice and
the design of interventions to promote adherence to
HAART. Intervening to alleviate symptoms may be
an economical and clinically relevant way to optimise
adherence. Siegel, Schrimshaw, and Dean (1999)
found that individuals tended to resort to non-
adherence before discussing symptoms with their
clinicians. Clinicians should encourage patients to
report any new symptoms so that the likely cause,
duration and possible treatment of each can be
discussed. It should be noted that symptoms are
subjective experiences, and those that are not con-
sidered to be clinically significant may be perceived as
severe by the patient. Indeed, previous studies found
that low adherence was associated with patients’
perceptions of symptoms, but not by physician
estimates of symptoms (Carrieri et al., 2001; Duran
et al., 2001) and that providers underestimated the
presence and intensity of symptoms (Justice, Rabe-
neck, Hays, Wu & Bozzette, 1999). Furthermore,
adherence may be increased by interventions which
enhance individuals’ perceptions of their continued
necessity for HAART in the context of persistent
HAART-side effects. Finally, the relationships iden-
tified in this study emphasise the need to continually
develop new and better drugs, which have fewer side
effects and thereby facilitate adherence.
References
Aikens, J.E., Nease, D.E., Jr., Nau, D.P., Klinkman, M.S.,
& Schwenk, T.L. (2005). Adherence to maintenance-
phase antidepressant medication as a function of
patient beliefs about medication. Annals of Family
Medicine, 3, 2330.
Ammassari, A., Antinori, A., Aloisi, M.S., Trotta, M.P.,
Murri, R., Bartoli, L., et al. (2004). Depressive
symptoms, neurocognitive impairment, and adherence
to highly active antiretroviral therapy among HIV-
infected persons. Psychosomatics, 45(5), 394402.
Ammassari, A., Murri, R., Pezzotti, P., Trotta, M.P.,
Ravasio, L., De Longis, P., et al. (2001). Self-reported
symptoms and medication side effects inﬂuence adher-
ence to highly active antiretroviral therapy in persons
with HIV infection. Journal of Acquired Immune
Deﬁciency Syndromes, 28(5), 445449.
Bangsberg, D.R. (2006). Less than 95% adherence to
nonnucleoside reverse-transcriptase inhibitor therapy
can lead to viral suppression. Clinical Infectious Dis-
eases, 43(7), 939941.
Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S.,
Pusterla, L., Fortuna, P., et al. (2000). Incidence of
adverse reactions in HIV patients treated with protease
inhibitors: A cohort study. Coordinamento Italiano
Studio Allergia e Infezione da HIV (CISAI) Group.
Journal of Acquired Immune Deﬁciency Syndromes,
23(3), 236245.
British HIV Association (BHIVA). (1997). Guidelines Co-
ordinating Committee. British HIV association guide-
lines for antiretroviral treatment of HIV seropositive
individuals. Lancet, 349(9058), 10861092.
British HIV Association (BHIVA). (2001). Guidelines for
the treatment of HIV-infected adults with antiretro-
viral therapy. HIV Medicine, 2(4), 276313.
British HIV Association (BHIVA). (2003). Guidelines for
the treatment of HIV-infected adults with antiretro-
viral therapy. HIV Medicine, 4(Suppl. 1), 114.
Brown, C., Battista, D.R., Bruehlman, R., Sereika, S.S.,
Thase, M.E., & Dunbar-Jacob, J. (2005). Beliefs about
antidepressant medications in primary care patients:
Relationship to self-reported adherence. Medical Care,
43, 12031207.
Carrieri, P., Cailleton, V., Le Moing, V., Spire, B.,
Dellamonica, P., Bouvet, E., et al. (2001). The dynamic
of adherence to HAART: Results from the French
526 V. Cooper et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
Ki
ng
's
 C
ol
le
ge
 L
on
do
n]
 A
t:
 1
0:
46
 4
 J
un
e 
20
09
National APROCO cohort. Journal of Acquired Im-
mune Deﬁciency Syndromes, 28(3), 232239.
Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford,
A.L., Neidig, J., Zwickl, B., et al. (2000). Self-reported
adherence to antiretroviral medications among parti-
cipants in HIV clinical trials: The AACTG adherence
instruments. Patient Care Committee & Adherence
Working Group of the Outcomes Committee of the
Adult AIDS Clinical Trials Group (AACTG). AIDS
Care, 12(3), 255266.
Ciesla, J.A., & Roberts, J.E. (2001). Meta-analysis of the
relationship between HIV infection and risk for
depressive disorders. American Journal of Psychiatry,
158(5), 725730.
Cohen, J., & Cohen, P. (1983). Applied multiple regression.
Hillsdale, NJ: Erlbaum.
Cooper, V., Buick, D., Horne, R., Lambert, N., Gellaitry,
G., Leake, H., et al. (2002). Perceptions of HAART
among gay men who have declined a treatment offer:
Preliminary results from an interview-based study.
AIDS Care, 14(3), 319328.
Duran, S., Spire, B., Rafﬁ, F., Walter, V., Bouhour, D.,
Journot, V., et al. (2001). Self-reported symptoms after
initiation of a protease inhibitor in HIV-infected
patients and their impact on adherence to HAART.
HIV Clinical Trials, 2(1), 3845.
Gifford, A.L., Bormann, J.E., Shively, M.J., Wright, B.C.,
Richman, D.D., & Bozzette, S.A. (2000). Predictors of
self-reported adherence and plasma HIV concentra-
tions in patients on multidrug antiretroviral regimens.
Journal of Acquired Immune Deﬁciency Syndromes,
23(5), 386395.
Golin, C., Liu, H., Hays, R.D., Miller, L.G., Beck, C.K.,
Ickovics, J., et al. (2002). Prospective study of pre-
dictors of adherence to combination antiretroviral
medication. Journal of General Internal Medicine, 17,
756765.
Gross, R., Bilker, W.B., Friedman, H.M., & Strom, B.L.
(2001). Effect of adherence to newly initiated antire-
troviral therapy on plasma viral load. AIDS, 15, 2109
2117.
Gross, R., Yip, B., Wood, E., Bangsberg, D., Montaner, J.,
& Hogg, R. (2006, February 58). Boosted PI are more
forgiving of suboptimal adherence than non-boosted PI
or NNRTI. 13th Conference on Retroviruses and
Opportunistic Infections, Denver, Colorado.
Horne, R. (1997). Representations of medication and
treatment: Advances in theory and measurement. In
K.J. Petrie & J.A. Weinman (Eds.), Perceptions of
health and illness: Current research and applications
(pp. 155188). London: Harwood Academic Press.
Horne, R. (2003). Treatment perceptions and self regula-
tion. In L.D. Cameron & H. Leventhal (Eds.), The self-
regulation of health and illness behaviour (pp. 138153).
London: Routledge.
Horne, R., Buick, D., Fisher, M., Leake, H., Cooper, V., &
Weinman, J. (2004). Doubts about necessity and
concerns about adverse effects: Identifying the types
of beliefs that are associated with non-adherence to
HAART. International Journal of STD and AIDS, 15,
3844.
Horne, R., Cooper, V., Gellaitry, G., Leake Date, H., &
Fisher, M. (2007) Patients’ perceptions of HAART in
relation to treatment uptake and adherence: The utility
of the necessity-concerns framework. Journal of Ac-
quired Immune Deﬁciency Syndromes, 45(3), 33441.
Horne, R., & Weinman, J. (2002). Self regulation and self
management in asthma: Exploring the role of illness
perceptions and treatment beliefs in explaining non-
adherence to preventer medication. Psychology and
Health, 17, 1732.
Horne, R., Weinman, J., & Hankins, M. (1999). The beliefs
about medicines questionnaire: The development and
evaluation of a new method for assessing the cognitive
representation of medication. Psychology and Health,
14, 124.
Justice, A.C., Rabeneck, L., Hays, R.D., Wu, A.W., &
Bozzette, S.A. (1999). Sensitivity, speciﬁcity, reliability,
and clinical validity of provider-reported symptoms: A
comparison with self-reported symptoms. Outcomes
Committee of the AIDS Clinical Trials Group. Journal
of Acquired Immune Deﬁciency Syndromes, 21(2), 126
133.
Leventhal, H., & Cameron, L. (1987). Behavioural theories
and the problem of compliance. Patient Education and
Counselling, 10, 117138.
Leventhal, H., Diefenbach, M., & Leventhal, E.A. (1992).
Illness cognition: Using common sense to understand
treatment adherence and affect cognition interactions.
Cognitive Therapy and Research, 16, 143163.
Leventhal, H., Nerenz, D.R., & Sraus, A. (1982). Self
regulation and the mechanisms for symptom appraisal.
In D. Michanic (Ed.), Symptoms, illness behavior and
help seeking (pp. 5586). New York: Watson Aca-
demic.
Llewellyn, C., Miners, A., Lee, C., Harrington, C., &
Weinman, J. (2003). The illness perceptions and
treatment beliefs of individuals with severe haemophi-
lia and their role in adherence to home treatment.
Health Psychology, 18, 185200.
Lucas, G.M., Chaisson, R.E., & Moore, R.D. (1999).
Highly active antiretroviral therapy in a large urban
clinic: Risk factors for virologic failure and adverse
drug reactions. Annals of Internal Medicine, 131(2), 81
87.
Mannheimer, S., Friedland, G., Matts, J., Child, C., &
Chesney, M. (2002). The consistency of adherence to
antiretroviral therapy predicts biologic outcomes for
human immunodeﬁciency virus-infected persons in
clinical trials. Clinical Infectious Diseases, 34(8),
11151121.
Moatti, J.P., Carrieri, M.P., Spire, B., Gastaut, J.A.,
Cassuto, J.P., & Moreau, J. (2000). Adherence to
HAART in French HIV-infected injecting drug users:
The contribution of buprenorphine drug maintenance
treatment. The Manif 2000 study group. AIDS, 14(2),
151155.
Mocroft, A., Ledergerber, B., Katlama, C., Kirk, O., Reiss,
P., d’Arminio Monforte, A., EuroSIDA study group.
AIDS Care 527
D
o
w
n
lo
ad
ed
 B
y:
 [
Ki
ng
's
 C
ol
le
ge
 L
on
do
n]
 A
t:
 1
0:
46
 4
 J
un
e 
20
09
(2003). Decline in the AIDS and death rates in the
EuroSIDA study: An observational study. Lancet, 362,
2229.
Mocroft, A., Youle, M., Moore, A., Sabin, C., Madge, S.,
Lepri, A., et al. (2001). Reasons for modiﬁcation and
discontinuation of antiretrovirals: Results from a
single treatment centre. AIDS, 15(2), 185194.
Moss-Morris, R., Weinman, J., Petrie, K.J., Horne, R.,
Cameron, L., & Buick, D. (2002). The revised illness
perception questionnaire (IPQ-R). Psychology and
Health, 17(1), 116.
Neame, R., & Hammond, A. (2005). Beliefs about medica-
tions: A questionnaire survey of people with rheuma-
toid arthritis. Rheumatology, 44, 762767.
O’Brien, M.E., Clark, R.A., Besch, C., Myers, L., &
Kissinger, P. (2003). Patterns and correlates of dis-
continuation of the initial HAART regimen in an
urban outpatient cohort. Journal of Acquired Immune
Deﬁciency Syndromes, 34(4), 407414.
Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis,
E.N., Squier, C., et al. (2000). Adherence to protease
inhibitor therapy and outcomes in patients with HIV
infection. Annals of Internal Medicine, 133(1), 2130.
Siegel, K., Schrimshaw, E.W., & Dean, L. (1999). Symptom
interpretation: Implications for delay in HIV testing
and care among HIV-infected late middle-aged and
older adults. AIDS Care, 11(5), 525535.
Walsh, J.C., Mandalia, S., & Gazzard, B.G. (2002).
Responses to a 1 month self-report on adherence to
antiretroviral therapy are consistent with electronic
data and virological treatment outcome. AIDS, 16(2),
269277.
Watson, D., & Pennebaker, J.W. (1989). Health com-
plaints, stress, and distress: Exploring the central role
of negative affectivity. Psychological Review, 96(2),
234254.
Weinman, J., Petrie, K., Moss-Morris, R., & Horne, R.
(1996). The illness perception questionniare: A new
method for assessing the cognitive representation of
illness. Psychology and Health, 11, 431445.
Wood, E., Hogg, R.S., Yip, B., Harrigan, P.R., O’Shaugh-
nessy, M.V., & Montaner, J.S. (2003). Effect of
medication adherence on survival of HIV-infected
adults who start highly active antiretroviral therapy
when CD4 count is 0.2000.35010 (9) cells/L. Annals
of Internal Medicine, 39(10), 810816.
Zigmond, A.S., & Snaith, R.P. (1983). The hospital anxiety
and depression scale. Acta Psychiatrica Scandanavica,
67(6), 361370.
528 V. Cooper et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
Ki
ng
's
 C
ol
le
ge
 L
on
do
n]
 A
t:
 1
0:
46
 4
 J
un
e 
20
09
